What Is The Current and Historic Market Size Analysis Of The Cancer Clinical Decision Tools Market?
The cancer clinical decision tools market has seen considerable growth due to a variety of factors.
• In recent years, the market size for cancer clinical decision tools has seen substantial growth. The market, which was valued at $0.5 billion in 2024, is predicted to move up to $0.55 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 9.5%.
The profound growth experienced during this historical period can be credited to the rising cases of cancer, the escalating complication of cancer treatments, the swelling demand for personalized medicine, the increase in value-based healthcare adoption, the growing accessibility of cancer-related data, and government endorsements for cancer research and advancements.
What Are The Predictions for The Cancer Clinical Decision Tools Market in the Coming Years?
The cancer clinical decision tools market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, the market size of cancer clinical decision tools is projected to witness robust growth. The market valuation is expected to reach $0.79 billion by 2029, expanding at a compound annual growth rate (CAGR) of 9.8%.
The predicted growth during the forecast period could be linked to the worldwide aging population, enhanced patient involvement and collective decision-making, patient-oriented care, clinical studies, and evidence-supported medicine. Future trends potentially influencing this market growth could be developments in medical imaging, AI-predicted clinical decision support, telemedicine coupled with distance consultations, predictive analytics, unification and data norms, along with moral and regulatory considerations.
Which Drivers Are Accelerating Growth In The Cancer Clinical Decision Tools Market?
The global spike in cancer cases is expected to fuel the expansion of the cancer clinical decision tools market. As per the American Cancer Society's report in January 2022, it is predicted that about 1.9 million new cancer diagnoses and 609,360 cancer-related deaths will occur in the US alone, averaging out to about 1,670 deaths daily. Lung, prostate, bowel, and female breast cancer are the four most prevalent cancer types globally, making up 43% of all new cases. Hence, the escalating cancer prevalence globally will enhance the need for cancer clinical decision tools. These tools can expedite the treatment decision process, thereby boosting the growth of the cancer clinical decision tools market.
What Are The Core Segments Of The Global Cancer Clinical Decision Tools Market?
The cancer clinical decision tools market covered in this report is segmented –
1) By Type: Risk Assessment Tool(RAT), Qcancer
2) By End-User: Hospital, Clinics
Subsegments:
1) By Risk Assessment Tool (RAT): Family History Assessment, Genetic Testing and Counseling, Lifestyle and Environmental Risk Factors Evaluation
2) By Qcancer: Symptom Checker, Risk Calculator, Guideline-Based Recommendations
Pre-Book The Cancer Clinical Decision Tools Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Cancer Clinical Decision Tools Market?
Leading firms in the cancer clinical decision tools market, are uncovering novel products like the BenchMark Ultra Plus tissue staining system to stay ahead in the competition. This system enhances tissue staining for quicker and more precise pathology outcomes. For instance, in June 2022, F. Hoffmann-La Roche AG, a Swiss healthcare firm, released the BenchMark Ultra Plus tissue staining system. This system outshines with increased workflow efficacy, advanced testing procedures, and sustainability attributes. It enables pathologists to provide top-notch, timely findings to healthcare experts and patients. The BenchMark Ultra Plus system is the progressive step in the evolution of the BenchMark series; it automates the traditionally manual slide-by-slide actions, bringing a new wave in cancer diagnostics.
Who Are the Key Players In The Cancer Clinical Decision Tools Market?
Major companies operating in the cancer clinical decision tools market include:
• McKesson Corporation
• Medical Information Technology Inc.
• Philips Healthcare
• Siemens Healthineers AG
• Elsevier B.V.
• Macmillan Publishers Limited
• National Decision Support Company
• Cerner Corporation
• GE Healthcare
• Allscripts Healthcare Solutions Inc.
• Epic Systems Corporation
• RaySearch Laboratories AB
• Elekta AB
• Varian Medical Systems Inc.
• Accuray Incorporated
• F. Hoffmann-La Roche Ltd.
• Flatiron Health Inc.
• Tempus Labs Inc.
• NantHealth Inc.
• Syapse Inc.
• Inspirata Inc.
• Oncora Medical Inc.
• Prognos Health Inc.
• Deep 6 AI Inc.
• PathAI Inc.
• Enlitic Inc.
• Ibex Medical Analytics Ltd.
• Zebra Medical Vision Ltd.
• Aidoc Medical Ltd.
What Are The Regional Insights Into The Cancer Clinical Decision Tools Market?
North America was the largest region in the cancer clinical decision tools market in 2024. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
